This article first appeared on GuruFocus .
Release Date: November 04, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Medline Inc ( NASDAQ:MDLN ) raised its full-year 2026 organic sales guidance for the third consecutive quarter to 10%-10.5%, reflecting continued strong demand and commercial execution.
-
Third-quarter net sales grew 10% year-over-year to $7.9 billion, with growth across every segment and channel, including 14% growth in Supply Chain Solutions.
-
Medline Inc ( NASDAQ:MDLN ) is on track to achieve its full-year goal of $1 billion in total new customer signings, supported by a strong pipeline and recent wins with large health systems.
-
The company generated strong free cash flow of $1.8 billion in the first nine months of 2026 and improved net leverage to 2.5 times from 2.9 times last quarter.
-
Medline Inc ( NASDAQ:MDLN ) announced a newly authorized $1 billion share repurchase program and prepaid a $750 million term loan, demonstrating disciplined capital allocation and balance sheet strength.
Negative Points
-
Medline Inc ( NASDAQ:MDLN ) expects 2027 adjusted EBITDA growth in the low to mid-single-digits, trailing high single-digit net sales growth due to elevated inflation, operational investments, and quality-related spending.
-
Supply Chain Solutions adjusted EBITDA margin fell to 4.4% in the third quarter, driven by lower-margin new prime vendor customer mix, first-year rebates, and higher operating expenses.
-
Inflationary pressures have intensified, with estimated Middle East conflict-related costs rising to $80 million from $70 million, and the company now assumes elevated diesel, raw material, and finished goods costs persist through 2027.
-
The fire at the Tracy, California distribution center reduced third-quarter net income by $80 million, and full insurance recovery is still pending.
-
Medline Inc ( NASDAQ:MDLN ) is undertaking a multi-year Global Quality Action Plan requiring significant investments in people, processes, and technology, and recently exited the home care bed business, a roughly $60 million impact.
Q & A Highlights
Q: With raw material input costs up materially since last quarter's guidance, can you put parameters around the 2027 inflation magnitude, and how much latitude do you have to raise prices given the long-term nature of your contracts? A: CFO Mike Drazen said Middle East-related inflation is now expected near $80 million for 2026 versus the prior $70 million, driven by elevated raw materials, finished goods, and diesel near $6.25 per gallon. The 2027 framework assumes these costs remain elevated at current rates for the full year, which contributes to the low-to-mid-single-digit adjusted EBITDA growth outlook. CEO Jim Boyle added that price has never been a growth lever for Medline but rather a tool to offset sustainable COGS pressure, and the company's contract infrastructure allows those customer discussions when inflation proves persistent.
Q: How much of the 10.5% organic growth in Q3 came from existing customer growth versus 2026 implementations, and how will that mix evolve into 2027? A: CFO Mike Drazen said same-store sales remain very strong and consistent with prior quarters, without quantifying the split. The $2.4 billion of signings in 2025 are contributing about 65% of their revenue in 2026. For 2027, he noted the company does not expect a repeat of the record $2.4 billion signings but remains on track for $1 billion this year, supporting high-single-digit sales growth next year.
Q: What changed versus 90 days ago in Supply Chain Solutions margins, which came in at 4.4% in Q3 versus prior expectations of roughly 4.9% to 5%? A: CFO Mike Drazen attributed the shortfall to two factors: customer mix, including first-year rebates on the $2.4 billion of new signings and the economics of 2026 renewals, which accelerated versus expectations, plus higher operating expenses. He guided Supply Chain Solutions margin to remain in the mid-4s for the rest of the year and said the full-year impact is somewhat less than the roughly $100 million estimate implied, with the company working to offset it through back-end and vendor funding.
Q: Can you detail the restructuring program, how long since a similar action, and whether it is a one-time or continuous effort? A: CEO Jim Boyle said Medline constantly reviews the business for continuous improvement, and this enterprise-wide program is designed to streamline the organizational structure, reduce duplication, and fund investments. CFO Mike Drazen said the program carries approximately $20 million to $30 million in restructuring costs recorded in Q4 and excluded from adjusted EBITDA, and is expected to generate roughly $80 million to $90 million in annualized savings, primarily realized in 2027.
Q: On the global quality action plan, what is the total contemplated 2027 spend, and was the home care bed exit part of the plan or an independent decision? A: CEO Jim Boyle said the home care bed exit followed more than a year of work with the FDA and represents roughly $60 million in impact; it is not representative of the broader portfolio, and the company launched repair-or-replace options for the market. CFO Mike Drazen said the quality spend is not publicly quantified but is a growing component of the 2027 framework, increasing versus 2026 because second-half 2026 investments carry over on a full-year basis plus additional 2027 investments.
Q: What is the market opportunity in Canada for the prime vendor model, and how does the strategy compare to the U.S. playbook? A: CEO Jim Boyle said the Mohawk MedBuy contract is going extremely well, with five hospitals live and the rollout expected to finish by March 2027. He noted the Canadian reimbursement and contracting model differs from the U.S., so Medline is deliberately following a crawl-walk-run approach and has not yet sized the market, though other markets are already asking for access and he is extremely optimistic it could drive outsized growth.
Q: What percentage of prime vendor partners also buy lab and diagnostics supplies, and does conversion to Medline brand differ from broader MedSurg categories? A: CEO Jim Boyle said every acute and physician office customer has lab needs, and Medline sees about a 30% convertible opportunity in lab and diagnostics. The penetration playbook mirrors distribution: roughly 10% capture at signing, doubling of the opportunity with a new prime vendor win, then 3% to 4% annual growth. He added that the same trucks deliver MedSurg and lab supplies, so incremental distribution cost is minimal.
Q: How are the outsized 2025 prime vendor wins flowing through, and what is the profit cadence on 2026 signings heading into next year? A: CFO Mike Drazen said all $2.4 billion signed in 2025 is now live, with about 25% of revenue recognized in 2025, about 65% in 2026, and the remainder in 2027. Profitability on 2026 signings is consistent with prior history, with roughly 10% Medline brand conversion in year one and 2% to 4% thereafter.
Q: What is the cadence on pricing, and how much pricing is embedded in the initial 2027 framework? A: CEO Jim Boyle said Medline raises prices on January 1 and July 1, notifying customers 30 to 60 days in advance depending on the contract, and the increases offset only a portion of COGS rather than all of it. CFO Mike Drazen declined to comment on the specific amount of 2027 pricing.
Q: Can you discuss the hospital buying environment and what the midterm election outcome means for reimbursement and volumes? A: CEO Jim Boyle said Democrats may be better positioned to soften Medicare and Medicaid impacts, but patient volumes depend on access to care rather than politics. While some providers have reported surgical volume softness, Medline is seeing nice growth in Surgical Solutions through same-store sales gains and partnerships with faster-growing providers.
Q: What is the rationale and timing behind the new $1 billion share repurchase program, and does it change M&A priorities? A: CFO Mike Drazen said this is Medline's first buyback, funded by excess cash beyond business needs, with $3.6 billion in cash and short-term investments at quarter end and leverage improved to 2.5 times. The company will
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
